Capybio LLC

Accuronix is a biopharmaceutical company based in Saint Louis, MO, focused on developing innovative cancer therapies that selectively target tumor cells, enhancing treatment efficacy while minimizing toxicity. Their lead candidate, ACXT-3102, is a novel small molecule drug conjugate designed for preclinical application against pancreatic adenocarcinoma and other rare tumors, leveraging a unique delivery mechanism that promotes cancer cell death through apoptosis and ferroptosis. Committed to addressing significant unmet needs in oncology, Accuronix is expanding its library of receptor ligands to improve drug targeting strategies, particularly against the -2 receptor which is overexpressed in various cancers. The company's mission centers on partnering with academic and research institutions to advance its groundbreaking therapies toward regulatory designations and eventual clinical application. Generated from the website

BioGenerator Ventures is a St. Louis-based investment firm that specializes in creating, building, and investing in companies that address critical challenges in human health and agriculture. With a portfolio spanning various sectors within the life sciences, including therapeutics, diagnostics, medical devices, research tools, agriculture, and healthcare, BioGenerator Ventures has invested $39 million into startups and has helped its portfolio companies raise over $2.6 billion in funding. Through its BioGenerator Labs engine, BioGenerator Ventures provides catalytic investments to life sciences companies, offering a suite of resources such as technology, talent, proof of concept grants, coaching, grant training, and innovative laboratory space to accelerate the growth of new ventures. With a track record of successful exits and partnerships, BioGenerator Ventures has played a crucial role in the development and maturation of companies like Geneoscopy, Medibeacon, and Benson Hill, helping them achieve significant milestones and become venture-funded and revenue-generating entities.Generated from the website

Immunophotonics, Inc. is a pioneering biotechnology company based in Saint Louis, MO, dedicated to unlocking the potential of the immune system through the development of a new class of therapeutics. Their proprietary glycan polymer technology stimulates antigen capture and uptake, triggering an immune response that enables the rejection of cancer and other diseases. With practical applications in interventional oncology, immunotherapy, and vaccine enhancement, Immunophotonics aims to elevate modern medicine and improve outcomes for patients worldwide. Through their innovative approach, Immunophotonics is transforming conventional surgical interventions into systemically active immunotherapies, upregulating T-cell activation, downregulating T-cell exhaustion, and driving stronger immune responses. Their powerful immunoadjuvant, IP-001, has the potential to enhance antigen-specific immunity against infectious diseases, including SARS-CoV-2, and increase the efficacy of vaccines. Committed to global human health, Immunophotonics is at the forefront of advancing medical treatments and improving patient outcomes.Generated from the website